januvia 100mg comprimido recubierto
merck sharp & dohme peru s.r.l. - droguerÍa - sitagliptina; - comprimido recubierto - por comprimido - - sitagliptina
januvia 50mg comprimido recubierto
merck sharp & dohme peru s.r.l. - droguerÍa - sitagliptina; - comprimido recubierto - por comprimido - - sitagliptina
lincomicina 600mg/2ml solucion inyectable
sanofi - aventis del peru s.a. - clorhidrato de lincomicina; - solucion inyectable - por ampolla - lincomicina
rheumocam 5 mg/ml solucion inyectable para perros y gatos
chanelle pharmaceutical manufacturing ltd. - meloxicam - soluciÓn inyectable - excipientes: etanol al 96 por ciento, poloxamero 188, macrogol 400, glicilglicina, acido clorhidrico, meglumina, agua para preparaciones inyectables, edetato de disodio, hidroxido de sodio (e-524) - meloxicam - gatos, perros
stronghold 240 mg solucion para uncion dorsal puntual para perros 20,1-40,0 kg
zoetis belgium sa - selamectina - soluciÓn para unciÓn dorsal puntual - excipientes: butilhidroxitolueno - selamectina - perros
virbagen omega
virbac s.a. - interferón omega recombinante de origen felino - inmunoestimulantes, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. en gatos infectados por vif, la mortalidad fue baja (5%) y no fue influenciada por el tratamiento.
plavix
sanofi winthrop industrie - sulfato de hidrógeno y clopidogrel - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevención de aterotrombóticos y tromboembólicos eventos en la fibrillationin pacientes adultos con fibrilación auricular que tienen al menos un factor de riesgo de eventos vasculares, no son adecuados para el tratamiento con vitamina k antagonistas y que tienen un bajo riesgo de sangrado, clopidogrel está indicado en combinación con aas para la prevención de la aterotrombótico y eventos tromboembólicos, incluyendo infarto cerebral.
trayenta®
west-ward columbus inc. - linagliptina - tableta recubierta - 5 mg
sertal 10 mg /ml solución oral gotas
megapharma labs de ceam, sociedad anónima - solución oral - 10 mg/ml